Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel Sells 36,256 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 36,256 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $11.42, for a total value of $414,043.52. Following the transaction, the executive vice president now owns 735,074 shares in the company, valued at approximately $8,394,545.08. This trade represents a 4.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

David Sponsel also recently made the following trade(s):

• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The shares were sold at an average price of $10.00, for a total transaction of $2,380.00.

Alphatec Price Performance

NASDAQ:ATEC opened at $12.14 on Wednesday. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The company has a 50-day moving average of $10.20 and a 200-day moving average of $8.08. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $17.34. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -9.48 and a beta of 1.43.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ATEC. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research report on Tuesday, January 14th. Barclays increased their price objective on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. Finally, Needham & Company LLC upped their target price on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.56.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATEC. R Squared Ltd bought a new stake in shares of Alphatec in the 4th quarter valued at approximately $29,000. Nisa Investment Advisors LLC grew its position in Alphatec by 973.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after acquiring an additional 4,234 shares during the period. Newton One Investments LLC bought a new position in shares of Alphatec during the fourth quarter valued at $50,000. XTX Topco Ltd acquired a new stake in shares of Alphatec in the 3rd quarter valued at $69,000. Finally, Ballentine Partners LLC bought a new stake in shares of Alphatec in the 4th quarter worth about $120,000. Institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.